Abstract
Methods: For this survey we used a multicenter North-Holland cohort of 438 CD patients treated with ADA. Twenty-nine of these had previously been treated with IFX and received a second IFX treatment after failing ADA. Short-term and prolonged response to IFX was assessed retrospectively by reviewing clinical records. Results: 29 patients (62% luminal CD, 7% fistulising CD, 31% both) from 8 hospitals were included with complete follow-up data up to 18 months. IFX was re-started at 5mg/kg in 20/39 (69%), 7.5mg/kg in 1 patient and at 10mg/kg in 8/29 (28%), at intervals varying between 4 and 8 weeks. Dose escalation was done in 8/29 (28%) of patients during retreatment with IFX. Twenty patients (69%) were on concomitant immune modulators at the re-introduction of IFX and 3 (10%) patients experienced adverse events: acute infusion reaction (n = 2, 7%) and delayed hypersensitivity reaction (n = 1, 3%). Clinical outcome is shown in Figure 1.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
